A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

This study is testing a new drug called AC676 for adults with certain types of relapsed or treatment-resistant B-cell blood cancers — cancers that have come back or stopped responding to previous treatments. AC676 works by targeting and degrading a protein that some blood cancer cells need to survive. **You may be eligible if:** - You are at least 18 years old - You have been diagnosed with one of the following blood cancers that has relapsed or is no longer responding to treatment: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL, non-GCB subtype), marginal zone lymphoma (MZL), or Waldenström macroglobulinemia (WM) - You have already received at least 2 prior treatments, or there are no other treatments expected to provide meaningful benefit **You may NOT be eligible if:** - You have not tried at least 2 prior systemic therapies - You have other significant health conditions that make you ineligible Talk to your doctor to see if this trial is right for you.